Copenhagen: Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a "strategic partnership" with OpenAI to accelerate the development of new medications.
Like other drugmakers, Novo Nordisk is banking heavily on artificial intelligence to test new treatments and vaccines and bring them to market faster for less money.
Novo Nordisk said the partnership would place it "at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster".
No financial details of the partnership were disclosed.
"This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care," OpenAI CEO Sam Altman said.
Pilot programmes will be launched across several business areas "with full integration by the end of 2026", the statement added.
